Skip to main content
Clinical Trials/ITMCTR2000004102
ITMCTR2000004102
Not Yet Recruiting
Phase 4

A prospective non-randomized controlled clinical study evaluating the effectiveness and safety of Yuye Jiedu Granules in the treatment of children with influenza wind-heat and dampness syndrome

The First Teaching Hospital of Tianjin University of TCM0 sitesTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Childhood influenza
Sponsor
The First Teaching Hospital of Tianjin University of TCM
Status
Not Yet Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
The First Teaching Hospital of Tianjin University of TCM

Eligibility Criteria

Inclusion Criteria

  • (1\) Meet the clinical diagnostic criteria for influenza in children, and the rapid influenza antigen test (colloidal gold immunochromatographic method) is positive;
  • (2\) Meet the TCM syndrome differentiation standard of wind\-heat and dampness;
  • (3\) Aged from 1 to 13 years old (\<14 years old);
  • (4\) Course of fever \<\=48h;
  • (5\) The informed consent process complies with the regulations, and the legal representative or the child (\>\=8 years old) jointly signs the informed consent form.

Exclusion Criteria

  • (1\) Suffering from pharyngeal conjunctival fever, herpetic angina, purulent tonsillitis, etc.;
  • (2\) Influenza complications such as sinusitis, otitis media, bronchitis, pneumonia, nervous system damage, heart damage, myositis and rhabdomyolysis, septic shock have occurred;
  • (3\) Severe or critical cases of influenza;
  • (4\) Antiviral drugs have been used within 48 hours before this visit;
  • (5\) Have received influenza vaccine within 12 months before the start of the test;
  • (6\) Receiving steroid therapy or other immunosuppressive therapy systemically;
  • (7\) History of epilepsy or high fever convulsion;
  • (8\) Patients with severe malnutrition, rickets, and serious primary diseases of the heart, brain, liver, kidney and hematopoietic system;
  • (9\) Allergic to test drugs;
  • (10\) According to the judgment of the investigator, there are other diseases or conditions that reduce the possibility of enrollment or complicate enrollment, such as unstable living environment, inconvenient transportation, etc. that may easily cause loss to follow\-up.

Outcomes

Primary Outcomes

Not specified

Similar Trials